Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on "Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis".
作者信息
Nakamura Toru, Nakano Masahito, Tsutsumi Tsubasa, Amano Keisuke, Kawaguchi Takumi
机构信息
Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
出版信息
Clin Mol Hepatol. 2024 Oct;30(4):705-708. doi: 10.3350/cmh.2024.0372. Epub 2024 May 20.
Abstract
摘要
相似文献
1
Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on "Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis".代谢功能障碍相关脂肪性肝病是病毒和酒精相关肝细胞癌中普遍存在的潜在协同因素：关于“代谢功能障碍相关脂肪性肝病相关肝细胞癌的全球患病率：系统评价和荟萃分析”的社论
Clin Mol Hepatol. 2024 Oct;30(4):705-708. doi: 10.3350/cmh.2024.0372. Epub 2024 May 20.
2
Impact of metabolic dysfunction-associated fatty liver disease on liver transplant recipients with hepatitis B virus-related hepatocellular carcinoma.代谢功能障碍相关脂肪性肝病对乙型肝炎病毒相关肝细胞癌肝移植受者的影响。
Eur J Clin Nutr. 2024 Feb;78(2):107-113. doi: 10.1038/s41430-023-01363-y. Epub 2023 Nov 7.
3
Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma.代谢相关脂肪性肝病和非酒精性脂肪性肝病诊断对肝癌患者接受肝移植的影响。
Front Endocrinol (Lausanne). 2024 Apr 15;15:1306091. doi: 10.3389/fendo.2024.1306091. eCollection 2024.
4
Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis.全球代谢功能障碍相关脂肪性肝病相关肝细胞癌的患病率：系统评价和荟萃分析。
Clin Mol Hepatol. 2024 Jul;30(3):436-448. doi: 10.3350/cmh.2024.0109. Epub 2024 Apr 16.
5
Increased prevalence but decreased survival of nonviral hepatocellular carcinoma compared to viral hepatocellular carcinoma in recent ten years.近十年来，非病毒性肝细胞癌的发病率增加，但生存率却低于病毒性肝细胞癌。
Sci Rep. 2024 Apr 20;14(1):9068. doi: 10.1038/s41598-024-59668-2.
6
Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.代谢功能障碍相关脂肪性肝病增加慢性乙型肝炎患者不良结局的风险。
JHEP Rep. 2021 Aug 8;3(5):100350. doi: 10.1016/j.jhepr.2021.100350. eCollection 2021 Oct.
7
Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease.乙型肝炎相关肝细胞癌合并代谢相关脂肪性肝病患者的生存情况
Diabetes Metab Syndr Obes. 2023 Aug 2;16:2283-2293. doi: 10.2147/DMSO.S416280. eCollection 2023.
8
Metabolic dysfunction-associated fatty liver disease related hepatocellular carcinoma in China: An increasing problem: Letter to the edior on "Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis".中国代谢功能障碍相关脂肪性肝病相关肝细胞癌：一个日益严重的问题：致编辑的信，主题为“代谢功能障碍相关脂肪性肝病相关肝细胞癌的全球患病率：系统评价和荟萃分析”
Clin Mol Hepatol. 2024 Oct;30(4):965-969. doi: 10.3350/cmh.2024.0386. Epub 2024 Jun 18.
9
Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Viral Hepatitis: The Interlink.代谢功能障碍相关脂肪性肝病与慢性病毒性肝炎：内在联系
Pathogens. 2024 Jan 10;13(1):68. doi: 10.3390/pathogens13010068.
10
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives.慢性乙型肝炎合并代谢相关脂肪性肝病：挑战与展望。
Clin Mol Hepatol. 2023 Apr;29(2):320-331. doi: 10.3350/cmh.2022.0422. Epub 2023 Feb 1.
引用本文的文献
1
Temporal Trends in Cardiovascular Mortality in Underlying Viral Hepatitis: A Retrospective Analysis of Gender, Racial/Ethnic, and Regional Disparities.潜在病毒性肝炎患者心血管疾病死亡率的时间趋势：性别、种族/民族及地区差异的回顾性分析
JGH Open. 2025 Jul 27;9(8):e70235. doi: 10.1002/jgh3.70235. eCollection 2025 Aug.
2
Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research.代谢（功能障碍）相关脂肪性肝病指标及其对肝脏研究的贡献。
Hepatol Int. 2024 Dec;18(6):1740-1755. doi: 10.1007/s12072-024-10731-0. Epub 2024 Oct 16.
3
Hepatocellular carcinoma surveillance after sustained virological response in chronic hepatitis C: Editorial on "Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-analysis".慢性丙型肝炎持续病毒学应答后的肝细胞癌监测：关于“丙型肝炎病毒持续病毒学应答后肝细胞癌的无创预测：系统评价与荟萃分析”的社论
Clin Mol Hepatol. 2025 Jan;31(1):261-263. doi: 10.3350/cmh.2024.0795. Epub 2024 Sep 20.
4
Metabolic dysfunction-associated fatty liver disease related hepatocellular carcinoma in China: An increasing problem: Letter to the edior on "Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis".中国代谢功能障碍相关脂肪性肝病相关肝细胞癌：一个日益严重的问题：致编辑的信，主题为“代谢功能障碍相关脂肪性肝病相关肝细胞癌的全球患病率：系统评价和荟萃分析”
Clin Mol Hepatol. 2024 Oct;30(4):965-969. doi: 10.3350/cmh.2024.0386. Epub 2024 Jun 18.
本文引用的文献
1
Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis.全球代谢功能障碍相关脂肪性肝病相关肝细胞癌的患病率：系统评价和荟萃分析。
Clin Mol Hepatol. 2024 Jul;30(3):436-448. doi: 10.3350/cmh.2024.0109. Epub 2024 Apr 16.
2
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.特瑞利木单抗联合度伐利尤单抗治疗不可切除肝细胞癌。
NEJM Evid. 2022 Aug;1(8):EVIDoa2100070. doi: 10.1056/EVIDoa2100070. Epub 2022 Jun 6.
3
Immunotherapy and transplantation for hepatocellular carcinoma.免疫疗法与肝肿瘤移植。
J Hepatol. 2024 May;80(5):822-825. doi: 10.1016/j.jhep.2024.01.011. Epub 2024 Jan 20.
4
Impact of non-obese metabolic dysfunction-associated fatty liver disease on risk factors for the recurrence of esophageal squamous cell carcinoma treated with endoscopic submucosal dissection: A multicenter study.非肥胖型代谢功能障碍相关脂肪性肝病对接受内镜黏膜下剥离术治疗的食管鳞状细胞癌复发危险因素的影响：一项多中心研究
Hepatol Res. 2024 Feb;54(2):201-212. doi: 10.1111/hepr.13973. Epub 2023 Oct 18.
5
MAFLD: an optimal framework for understanding liver cancer phenotypes.MAFLD：理解肝癌表型的最佳框架。
J Gastroenterol. 2023 Oct;58(10):947-964. doi: 10.1007/s00535-023-02021-7. Epub 2023 Jul 20.
6
Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity.非肥胖型非酒精性脂肪性肝病与内脏型肥胖、肌肉减少症和肌内脂肪变性的相关性。
Clin Mol Hepatol. 2023 Oct;29(4):987-1001. doi: 10.3350/cmh.2023.0035. Epub 2023 Jul 5.
7
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment.非酒精性脂肪性肝炎相关肝细胞癌：发病机制与治疗。
Nat Rev Gastroenterol Hepatol. 2023 Aug;20(8):487-503. doi: 10.1038/s41575-023-00754-7. Epub 2023 Mar 17.
8
The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma.代谢功能障碍相关脂肪性肝病对非病毒性肝细胞癌患者乐伐替尼治疗的有益影响。
Hepatol Res. 2023 Feb;53(2):104-115. doi: 10.1111/hepr.13843. Epub 2022 Nov 6.
9
Lean/normal-weight metabolic dysfunction-associated fatty liver disease is a risk factor for reflux esophagitis.瘦/正常体重代谢功能障碍相关脂肪性肝病是反流性食管炎的一个危险因素。
Hepatol Res. 2022 Aug;52(8):699-711. doi: 10.1111/hepr.13795. Epub 2022 Jun 7.
10
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region.MAFLD改善了亚太地区肝脏疾病的临床实践。
Clin Mol Hepatol. 2022 Apr;28(2):150-163. doi: 10.3350/cmh.2021.0310. Epub 2021 Nov 10.
Zotero 插件